|
Characteristics
|
OP group (n = 8)
|
Osteopenia group (n = 28)
|
Normal group (n = 29)
|
P value
|
|---|
|
BMI
|
22.4 ± 4.3 (17.3–28.5)
|
25.5 ± 4.8 (16.6–39.5)
|
27.0 ± 4.3 (17.5–38.9)
|
0.040
|
|
Male gender, n (%)
|
8 (100%)
|
25 (89.3%)
|
23 (79.3%)
|
0.271
|
|
Age at outpatient visit (years)
|
28.3 ± 12.5 (17–54)
|
35.3 ± 8.8 (21–54)
|
32.9 ± 7.9 (21–54)
|
0.143
|
|
Age at onset (years)
|
18.5 ± 3.8 (14–24)
|
23.0 ± 5.9 (15–38)
|
25.0 ± 6.1 (15–39)
|
0.021
|
|
Duration of AS (years)
|
10.0 ± 12.7 (0–37.0)
|
12.5 ± 10.5 (0.5–37.0)
|
8.1 ± 6.8 (0–22.0)
|
0.214
|
|
Diagnosis delay (years)
|
4.6 ± 6.8 (0.0–18.0)
|
6.11 ± 7.23 (0–27.0)
|
5.3 ± 7.4 (0–33.0)
|
0.855
|
|
EAMs, n (%)
|
|
Uveitis
|
0
|
2 (7.1%)
|
2 (6.9%)
|
0.744
|
|
IBD
|
0
|
2 (7.1%)
|
2 (6.9%)
|
0.744
|
|
Family history, n (%)
|
3 (37.5%)
|
7 (25.0%)
|
4 (13.8%)
|
0.302
|
|
HLA-B27 positivity, n (%)
|
8 (100%)
|
26 (92.9%)
|
27 (93.1%)
|
0.744
|
|
Current use of NSAIDs, n (%)
|
5 (62.5%)
|
16 (57.1%)
|
22 (75.9%)
|
0.325
|
|
Current use of DMARDs, n (%)
|
5 (62.5%)
|
12 (42.9%)
|
18 (62.1%)
|
0.308
|
|
ESR (mm)
|
30.9 ± 21.2 (2–65)
|
35.8 ± 21.6 (3–93)
|
28.3 ± 18 (8–91)
|
0.383
|
|
CRP (mg/L)
|
19.2 ± 10.9 (3.5–35.2)
|
33.4 ± 32.9 (3.2–133.0)
|
22.5 ± 22.8 (1.9–100.0)
|
0.222
|
|
hsCRP (mg/L)
|
16.8 ± 13.2 (0.1–34.2)
|
31.9 ± 34.9 (0.8–137.4)
|
21.8 ± 24.2 (0.2–114.6)
|
0.277
|
|
BASDAI
|
3.9 ± 1.8 (1.4–5.8)
|
4.3 ± 2.0 (0.6–8.4)
|
3.1 ± 2.1 (0.4–7.8)
|
0.094
|
|
BASFI
|
2.4 ± 1.7 (0.5–5.5)
|
2.4 ± 1.7 (0.3–6.3)
|
1.8 ± 1.3 (0.2–4.0)
|
0.269
|
|
SF-12 PCS
|
35.1 ± 15.5 (16.5–58.4)
|
34.9 ± 11.6 (18.2–55.4)
|
40.7 ± 11.0 (18.5–55.9)
|
0.158
|
|
SF-12 MCS
|
36.1 ± 15.9 (17.1–55.4)
|
37.4 ± 11.6 (20.3–57.9)
|
42.2 ± 10.0 (21.4–55.9)
|
0.197
|
|
ASQOL
|
7.5 ± 5.9 (2–17)
|
7.0 ± 4.2 (1–16)
|
5.5 ± 4.2 (0–14)
|
0.344
|
|
HHS
|
72.5 ± 27.9 (24–100)
|
68.6 ± 20.8 (36–100)
|
83.6 ± 13.1 (48–99)
|
0.013
|
|
BASRI-Hip
|
1.9 ± 1.3 (0–3)
|
2.5–1.3 (0–4)
|
1.2 ± 1.2 (0–4)
|
0.002
|
|
CFI
|
3.4 ± 1.0 (1.7–4.8)
|
3.5 ± 0.9 (2.2–5.8)
|
3.6 ± 0.7 (2.1–5.0)
|
0.763
|
|
MCFI
|
2.1 ± 0.3 (1.8–2.7)
|
2.2 ± 0.2 (1.8–2.6)
|
2.2 ± 0.3 (1.3–3.0)
|
0.766
|
|
CBR
|
0.4 ± 0.1 (0.3–0.6)
|
0.5 ± 0.1 (0.3–0.7)
|
0.4 ± 0.1 (0.3–0.6)
|
0.094
|
|
CCR
|
0.5 ± 0.2 (0.36–0.9)
|
0.5 ± 0.1 (0.3–0.8)
|
0.5 ± 0.1 (0.3–0.7)
|
0.768
|
- The value of continuous variables was presented as mean ± standard deviation and the categorical variables were based on presented as number plus percentage
- Abbreviations: OP Osteoporosis, BMI Body mass index, AS Ankylosing spondylitis, EAMs Extra-articular manifestations, IBD Inflammatory bowel disease, NSAIDs Nonsteroidal anti-inflammatory drugs, DMARDs Disease modifying antirheumatic drugs, ESR Erythrocyte sedimentation rate, CRP C reactive protein, hsCRP High sensitive C reactive protein, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, SF-12 PCS Short form-12 physical component summary, SF-12 MCS Short form-12 mental component summary, ASQOL Ankylosing spondylitis quality of life, HHS Harris hip score, BASRI-Hip The bath ankylosing spondylitis radiology hip index
